MindMed Reports Third Quarter 2023 Financial Results and Business Highlights

Contributed by: Business Wire

Logo

Tags

Biotechnology

Neurology

Other Health

Health

Clinical Trials

Mind Medicine

More Like This

MindMed Reports 2023 Financial Results and Business Updates

MindMed Reports First Quarter 2024 Financial Results and Business Updates

MindMed Reports Second Quarter 2024 Financial Results and Business Updates

MindMed Reports Third Quarter 2024 Financial Results and Business Updates

MindMed Announces Business Update and Anticipated Milestones for 2024

MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder

MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)

MindMed to Present at Upcoming May Medical Conferences